<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526083</url>
  </required_header>
  <id_info>
    <org_study_id>EP0013</org_study_id>
    <secondary_id>2011-004911-21</secondary_id>
    <nct_id>NCT01526083</nct_id>
  </id_info>
  <brief_title>Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males</brief_title>
  <official_title>Single-center, Open-label, Randomized 2-way Crossover Study of the Effect of Lacosamide 200 mg Twice Daily on the Single-dose Pharmacokinetics and Pharmacodynamics of Warfarin (25 mg) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of Lacosamide 200 mg twice a day (bid)
      on single dose pharmacokinetics (PK) and pharmacodynamics (PD) of Warfarin (25 mg) in healthy
      male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Warfarin plasma concentration versus time curve from time 0 to infinity, AUC (Warfarin)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Warfarin plasma concentration versus time curve from time 0 to the last quantifiable level, AUC0-t(Warfarin)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single warfarin dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Warfarin plasma concentration (Cmax)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum prothrombin time (PTmax)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single warfarin dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Warfarin area under the prothrombin time (PT) versus time curve (PTAUC)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single warfarin dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Warfarin maximum international normalized ratio (INRmax)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Warfarin area under the International Normalized Ratio (INR) versus time curve (INRAUC)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose in each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lacosamide trough plasma concentration (Ctrough)</measure>
    <time_frame>Morning pre dose sample on Days 3-10 or Days 24 -30 of Lacosamide BID dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum Warfarin plasma concentration (Tmax)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of Warfarin (T Â½)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance of Warfarin (CL /F)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of Warfarin (V /F)</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First order terminal elimination rate constant of Warfarin</measure>
    <time_frame>Multiple sampling from 0 -168 hours following administration of a single Warfarin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYP2C9 genotype</measure>
    <time_frame>Single measurement on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VKORC1 genotype</measure>
    <time_frame>Single measurement on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) during the duration of the study</measure>
    <time_frame>Duration of study is approximately 32 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate at 4 h post dose</measure>
    <time_frame>From pre dose to 4 h post dose Warfarin administration in each treatment period</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose Warfarin administration in each treatment period</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate at 24 h post dose</measure>
    <time_frame>From pre dose to 24 h post dose Warfarin administration in each treatment period</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate at 4 h post dose</measure>
    <time_frame>From pre dose to 4 h post dose Lacosamide (LCM) administration</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose LCM administration</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure at 4 h post dose</measure>
    <time_frame>From pre dose to 4 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure at 24 h post dose</measure>
    <time_frame>From pre dose to 24 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure at 4 h post dose</measure>
    <time_frame>From pre dose to 4 h post dose LCM administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose LCM administration</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure at 4 h post dose</measure>
    <time_frame>From pre dose to 4 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure at 24 h post dose</measure>
    <time_frame>From pre dose to 24 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure at 4 h post dose</measure>
    <time_frame>From pre dose to 4 h post dose LCM administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose LCM administration</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature at 4h post dose</measure>
    <time_frame>From pre dose to 4 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature at 24 h post dose</measure>
    <time_frame>From pre dose to 24 h post dose Warfarin administration in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature at 4 h post dose</measure>
    <time_frame>From pre dose to 4 h post dose LCM administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature at 12 h post dose</measure>
    <time_frame>From pre dose to 12 h post dose LCM administration</time_frame>
    <description>40-90 bpm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single dose of Warfarin on day 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of Warfarin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days</description>
    <arm_group_label>Single dose of Warfarin on day 3</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period
In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.
Duration: single dose</description>
    <arm_group_label>Single dose of Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers 18-55 years of age

          -  BMI 18.0-30.0 kg/m2 and weight at least 50 kg

          -  Tympanic body temperature 35.0-37.5Â°C (95 and 99.5Â°F) inclusive

        Exclusion Criteria:

          -  Volunteer has participated or is participating in any other clinical studies of
             investigational drug or another Investigational Medicinal Product (IMP) within the
             last 3 months

          -  Volunteer is not healthy (eg, taking any drug treatments, excessive amount of alcohol,
             cigarettes or caffeine, having any medical or emotional/psychological problems, a
             drug/alcohol abuse, having abnormal safety parameters)

          -  Volunteer is taking Warfarin or Non Steroidal Anti-Inflammatory Drug (NSAID)

          -  Volunteer has history of suicide attempt

          -  Volunteer has history of coagulation abnormalities, occult blood in stool,
             gastrointestinal ulcer, surgery within 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>1 877 822 9493</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>001</name>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Male Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

